Aoli Wang

PhD candidate

350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China

Tel:+86-551-65595117

E-mail: kitty198702@hmfl.ac.cn

 

EDUCATION BACKGROUND

2014.09---now              PHD student
University of Science and Technology of China
2009.09—2012.07           Master of Natural Product Chemistry
Shenyang Pharmaceutical University
2005.09--2009.07            Bachelor of Chinese Traditional Medicine
Shenyang Pharmaceutical University

RESEARCH EXPERIENCE

2012.10—2014.09           Research Assistant
High Magnetic Field Laboratory Chinese Academy of Sciences

 

PUBLICATIONS

  1. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu.* Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 2017, 8(11): 18359-18372. doi: 10.18632/oncotarget.15443
  2. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, and Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01907.
  3. Xiaofei Liang#, Fengchao Lv#, Beilei Wang#, Kailin Yu#, Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchun Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01413.
  4. Hong Wu#， Qiong Huang#， Ziping Qi#， Yongfei Chen#,Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Xiaoxiang Li, Nathanael S. Gray, Jing Liu*, Wei Wei*, Qingsong Liu*. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports 2017, DOI : 10.1038/s41598-017-00482-4.
  5. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu*, Cai-Hong Yun*, Jing Liu*. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur. J. Med.Chem. 2017, DOI: 10.1016/j.ejmech.2017.03.001.
  6. Hong Wu#, Aoli Wang#, Wei Zhang#, Beilei Wang#, Cheng Chen#,Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu*, Liang Chen*,Liu Qingsong*,“Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells,” Oncotarget 2015, 6(31): 31313-31322.
  7. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#,Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*,Liu Qingsong*. “Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.” J. Med. Chem. 2015, 58: 9625-9630.
  8. Hong Wu#, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Yongfei Chen#, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*, Liu Qingsong*, Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia. Leukemia 2016, 30(1): 173-81.
  9. Wu Hong#, Hu Chen#, Aoli Wang#, E L Weisberg#, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin,Liu Jing* and Liu Qingsong*,“Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML,” Leukemia 2016, 30(3): 754-757.
  10. Aoli Wang#, Hong Wu#, Cheng Chen#, Chen Hu#, Ziping Qi, Wenchao Wang, Kailin Yu, Xiaochuan Liu, Fengming Zou, Zheng Zhao, Jiaxin Wu, Juan Liu, Feiyang Liu, Wang Li, Richard M. Stone, Ilene A. Galinksy, James D. Griffin4, Shanchun Zhang, Ellen L. Weisberg, Jing Liu*, Qingsong Liu*. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget 2016, (20): 29131-42. 
  11. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Wang Li,, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang, Ellen L. Weisberg, Jing Liu*, Qingsong Liu*. Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances. Oncotarget 2016, 7(22): 32641-51.
  12. Hong Wu#, Aoli Wang#, Ziping Qi#, Xixiang Li#, Cheng Chen, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai, Ellen L. Weisberg, Jing Liu*, Qingsong Liu*. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 2016, 30(10): 2112-2116.
  13. Xiaochuan Liu#,Aoli Wang#, Xiaofei Liang#, Juanjuan Liu#, Fengming Zou, Cheng Chen, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi,Beilei Wang, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M.Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg, Xin Zhang*, Jing Liu*, Qingsong Liu*. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδinhibitor cytotoxicity in the B-cell malignancies. Oncotarget 2016, 7(33): 53515-53525.
  14. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Qingsong Liu*, Jing Liu*, Discovery of CHMFL-KIT-8140 as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of c-KIT Kinase. J. Med. Chem. 2016, 59(18): 8456-72.
  15. Aoli Wang#, Xiao-E Yan#, Hong Wu#, Wenchao Wang, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*,Cai-Hong Yun*, Qingsong Liu*. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 2016, 7(43): 69760-69769.
  16. Chanjuan Wana#, Bo Wu#, Zhenwei Song, Jiahai Zhang, Huiying Chu, Aoli Wang, Qingsong Liu, Yunyu Shi, Guohui Li, Junfeng Wang*. Insights into the molecular recognition of the granuphilin C2A domain with PI(4,5)P2. Chem. Phys. Lipids 2015, 186: 61-67.
  17. Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen#, Lu-Lu Kong#, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun, Zhimin Zhai, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget 2016, 7(29): 45562-45574.
  18. Feiyang Liu#, Wang J#, Xingxing Yang#, Binhua Li#, Hong Wu, Shuang Qi, Cheng Chen, Xiaochuan Liu, kailin Yu, Wenchao Wang, Zhao, Aoli Wang, Yongfei Chen, Li Wang, Nathanael S Gray*, Jing Liu*, Xin Zhang*, Qingsong Liu*. Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem. Biol. 2016, 11(6): 1537-43.
  19. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou, Cheng Chen, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Wang Li, Shanchun Zhang, Yuexiang Wang, Jing Liu*, Qingsong Liu *. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-79.
  20. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective and orally available BCR-ABL/SRC/p38 kinase inhibitor for Chronic Myeloid Leukemia. J. Med. Chem. 2016, 59(5): 1984-2004.

PATENTS

1. "Triciribine and its metabolite is sensitive to FLT3-ITD dependent AML!", Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong;Wang Wenchao; Chen Cheng;Hu Chen;Li Binhua; Ziping Qi; Yu Kailin;Wang Li. (2015) PCT/CN2015/092600
2. "A new type of FLT3 kinase inhibitors and its application!", Liu, Qingsong; Liu Jing;Li Binhua;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Yu Kailin;Wang Beilei; Wang Li. (2015) PCT/CN2015/090306
3. "FLT3 kinase new inhibitors and its application!", Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Wu Jiaxin; Liu Juan;Yu Kailin; Wang Wei; Wang Li; Wang Beilei. (2015) PCT/CN2015/086318
4. "A674563 is sensitive to FLT3-ITD dependent AML !", Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong; Chen Cheng; Hu Chen; Wang Wenchao; Liu Xiaochuan; Yu Kailin; Zhao Zheng; Wu Jiaxin; Liu Juan; Wang Li; Wang Beilei. (2015) PCT/CN2015/083717
5. "New class of BCR-ABL's kinase inhibitors", Liu Jing; Liu, Qingsong; Liang Xiaofei; Wang Beilei; Wang Aoli; Liu Xiaochuan; Chen Cheng; Qi Ziping; Wang Wenchao; Zhao Zheng; Wang Li. (2015) PCT/CN2015/081220
6. "New class of PI3K's kinase inhibitors!", Liu, Qingsong; Liu Jing;Zhang Xin;Liang Xiaofei;Liu Xiaochuan;Liu Juanjuan; Chen Cheng;Zhao Zheng;Wang Aoli; Wang Wenchao;Wu Hong; Wang Beilei; Wang Li. .(2015) PCT/CN2015/081240
7. "New application of Ibrutinib", Liu, Qingsong; Liu Jing; Wang Beilei; Wang Aoli; Wu Hong; Hu Chen; Wang Wenchao; Chen Cheng; Wang Li; Li Xixiang; Li Xiaoxiang; Xu Ziao.(2015) PCT/CN2015/081051
8. "New class of Bruton's tyrosine kinase inhibitors", Liu, Qingsong; Liu Jing; Chen Yongfei; Wu Hong; Wang Aoli; Wang Beilei; Hu Chen; Wang Wenchao; Chen Cheng.(2015) PCT/CN2015/071594

9. "Ibrutinib is sensitive to FLT3-ITD dependent AML", Liu, Qingsong; Liu Jing; Wu Hong; Hu Chen; Wang Aoli; Wang Wenchao; Chen Cheng; Li Xixiang; Zhao Zheng; Wang Li; Wang Beilei.(2014) PCT/CN2014/091375

1. 发明名称：一种新型布鲁顿酪氨酸激酶不可逆抑制剂
发明人：刘静， 刘青松， 梁前茅，陈永飞，陈程，王傲莉，吴宏，余凯琳，王伟，胡晨，王文超，亓爽，王蓓蕾，王黎  ；专利受理号：201610084082.1
2. 发明名称：一类新型的 EGFR 野生型和突变型的激酶抑制剂
发明人： 刘青松， 刘静， 李希祥，王傲莉，吴宏，余凯琳，胡晨，王文超，陈程，邹凤鸣，齐紫平，王黎，王蓓蕾 ； 专利受理号：201511030721.8
3. 发明名称：一种新型 EGFR 和 ALK 激酶的双重抑制剂
发明人： 刘静， 刘青松， 江桃山，王傲莉， 吴佳昕，吴宏，齐紫平，陈永飞，邹凤鸣，王文超，赵铮，王黎，王蓓蕾 ；专利受理号：201510946305.6
4. 发明名称：曲西立滨（Triciribine）及相关代谢产物对FLT3突变的急性白血病的应用
发明人：刘青松，刘静，王傲莉，吴宏，王文超，陈程，胡晨，李滨华，齐紫平，余凯琳，王黎 ；专利受理号：201510665488.4
5. 发明名称：一类新型的FLT3激酶抑制剂及其用途
发明人：刘青松， 刘静， 李滨华, 王傲莉，吴宏，陈程，王文超，胡晨，赵铮，余凯琳，王蓓蕾，王黎 ； 专利受理号：201510608850.4
6. 发明名称：FLT3激酶的新型抑制剂及其用途
发明人：刘青松，刘静，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾 ； 专利受理号：201510547224.9
7.发明名称：A674563在携带FLT3突变型基因的急性白血病中的新用途
发明人：刘青松， 刘静，王傲莉，吴宏，陈程，胡晨，王文超，刘晓川，余凯琳，赵铮，吴佳昕，刘娟，王黎，王蓓蕾  ；专利受理号：201510262944.0
8. 发明名称：一种新型的BCR-ABL激酶抑制剂
发明人：刘静，刘青松，梁小飞，王蓓蕾，王傲莉，刘晓川，陈程，齐紫平，王文超，赵铮，王黎  ； 专利受理号：201510172534.7
9. 发明名称：FLT3激酶的新型抑制剂及其用途
发明人：刘静，刘青松，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾 ； 专利受理号：201510028177.7
10. 发明名称：一种新型的 PI3K 激酶抑制剂
发明人：刘青松，刘静，张欣，梁小飞，刘晓川，刘娟娟，陈程，赵铮，王傲莉，王文超，吴宏，王蓓蕾，王黎  ；专利受理号：201410821908.9
11. 发明名称：一种新型结构的激酶抑制剂
发明人：刘青松，刘静，王强，刘飞扬，王蓓蕾，王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎 ； 专利受理号：201410757626.7
12. 发明名称：依鲁替尼对FLT3-ITD突变的急性白血病的应用
发明人：刘青松，刘静，吴宏，胡晨，王傲莉，王文超，陈程，李希祥，赵铮，王黎，王蓓蕾 ；  专利受理号：201410598948.1
13. 发明名称：依鲁替尼的新用途
发明人：刘青松，刘静，王蓓蕾，王傲莉，吴宏，胡晨，王文超，陈程，王黎，李希祥   ；专利受理号：201410258423.3
14. 发明名称：一种新型Bruton酪氨酸激酶抑制剂
发明人：刘青松，刘静，陈永飞，吴宏，王傲莉，王蓓蕾，胡晨，王文超，陈程

；  专利受理号：201410280931.1